PPIDT00271
Drug Information
| Name | Peginterferon beta-1a |
|---|---|
| Sequence | MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN |
| DrugBank_ID | DB09122 |
| Type | biotech |
| Indication | Peginterferon beta-1a is indicated for the treatment of adult patients with relapsing forms of MS, including relapsing-remitting disease, clinically isolated syndrome, and active progressive secondary disease.[L31428] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intramuscular |
30 MCG/0.5ML
|
| Solution | Subcutaneous |
|
| Injection, solution | Intramuscular |
125 ug/0.5mL
|
| Injection, solution | Intramuscular |
125 mcg
|
| Injection, solution | Intramuscular; Parenteral |
125 MCG
|
| Injection, solution | Parenteral; Subcutaneous |
63 MCG
|
| Injection, solution | Subcutaneous |
125 ug/0.5mL
|
| Injection, solution | Subcutaneous |
125 MCG
|
| Kit | Subcutaneous |
|
| Kit; liquid | Subcutaneous |
|
| Liquid | Subcutaneous |
125 mcg / 0.5 mL
|
| Liquid | Subcutaneous |
63 mcg / 0.5 mL
|
| Liquid | Subcutaneous |
94 mcg / 0.5 mL
|
| Injection | Subcutaneous |
125 mcg/0.5ml
|
| Injection; kit | Subcutaneous |
|
| Solution | Subcutaneous |
12500000 mcg
|
| Solution | Subcutaneous |
6300000 mcg
|
| Solution | Subcutaneous |
9400000 mcg
|